# US 2019/0167588 A1 · Blended formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167588 A1
- Document ID: US20190167588A1
- Status: Published application
- Kind: A1
- Application number: 15/739,570
- Filed: 2016-06-30
- Published: 2019-06-06
- Earliest claimed: 2015-06-30
- Assignees: Sequessome Technology Holdings Limited
- Applicants: Sequessome Technology Holdings Limited
- Inventors: William HENRY; Richard Wolf GARRAWAY
- Web page: https://patentgrep.com/patent/US20190167588A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 8/04: Dispersions; Emulsions
- A61K 8/14: Liposomes; Vesicles
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/618: having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/04: Antipruritics
- A61P 17/10: Anti-acne agents
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 33/30: Zinc; Compounds thereof
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

## Claims

### Claim 1

A formulation comprising a first colloidal dispersion and a second colloidal dispersion, wherein each colloidal dispersion comprises deformable colloidal particles each comprising a surfactant and optionally a phospholipid and a particle membrane, and one or more of the deformable colloidal particles of the first colloidal dispersion comprise a first modified component comprising a first agent of interest (AOI) wherein the first modified component is a lipid bonded to the first AOI and/or a surfactant bonded to the first AOI, wherein the entire of the first AOI is outside the particle membrane when the first AOI is external to the particle.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein one or more of the deformable colloidal particles of the second colloidal dispersion comprise a second modified component bonded to a second AOI and wherein the second modified component is a lipid bonded to the second AOI or a surfactant bonded to the second AOI, wherein the entire of the second AOI is outside the particle membrane when the second AOI is external to the particle and wherein the first AOI and the second AOI are different.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein one or more of the deformable colloidal particles of the first colloidal dispersion and/or one or more of the deformable colloidal particles of the second colloidal dispersion comprise one or more further AOIs and wherein each AOI is different.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the formulation comprises one or more further colloidal dispersions comprising further deformable colloidal particles comprising a surfactant and optionally a phospholipid and wherein one or more of the particles of the further dispersions comprise one or more further AOIs and wherein the first AOI, second AOI and each further AOI is different.

### Claim at position 5

5-9. (canceled)

### Claim 10 (depends on 1)

The formulation of claim 1, wherein the first particle comprises both a modified surfactant component and a modified lipid component.

### Claim 11 (depends on 1)

The formulation of claim 1, wherein the first AOI is bonded to the first modified component via a covalent bond.

### Claim 12 (depends on 1)

The formulation of claim 1, wherein the first AOI is selected from the group consisting of an element, an ion, an inorganic salt, a small molecule, an amino acid, a peptide, a protein, a carbohydrate, a lipid, a micronutrient, a macromolecule Of a macrocyclic molecule, zinc, ascorbate, tetrapeptide, tripeptide, salicylic acid, Vitamin D, tocopherol, menthol, zinc stearate, palmitoyl ascorbate, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, myristyl salicylate, tridecyl salicylate, vitamin D, and tocopherol linoleate or menthol.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The formulation of claim 1, wherein the formulation comprises chlorhexidine, salicylic acid, capsaicin, caffeine or tocopherol.

### Claim 16 (depends on 15)

The formulation of claim 15, wherein the chlorhexidine, salicylic acid, capsaicin, caffeine or tocopherol is not associated with the deformable colloidal particles.

### Claim at position 13

17-20. (canceled)

### Claim 21 (depends on 1)

The formulation of claim 1, wherein the lipid is phosphatidylcholine.

### Claim 22 (depends on 1)

The formulation of claim 1, wherein the surfactant is polysorbate 80.

### Claim 23 (depends on 1)

The formulation of claim 1, wherein the formulation further includes one or more buffers, chelators, humectants, lubricants, antioxidants, preservatives, microbicides, antimicrobials, emollients, co-solvents or thickeners.

### Claim 24 (depends on 1)

The formulation of claim 1, wherein the formulation comprises Carbopol® or methylcellulose.

### Claim at position 18

25-36. (canceled)

### Claim 37 (depends on 1)

A method of cosmetically improving the appearance of a subject, the method comprising topically applying the formulation of claim 1 to the subject's skin.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, wherein improving the appearance of a subject comprises improving the appearance of uneven skin tone and/or treating or preventing the formation of spots, blackheads and blemishes, reducing skin impurities and tightening and constricting pores in the skin and/or improving the appearance of periorbital skin via reducing the appearance of wrinkles, eye puffiness, lower eyelid bags or sagging and dark under-eye circles, improving the appearance of skin texture and preventing sun damage.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 1)

A method of treating a disease in a subject comprising topically applying the formulation of claim 1 to the subject wherein the disease is treated.

### Claim 43 (depends on 42)

The method of claim 42, wherein the disease is acne, dry skin, itchy skin, red skin, irritated skin, scaly skin, ageing skin, thinning skin, uneven skin tone, periorbital skin, photo-aged skin or dermatitis.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

A kit comprising one or more compartments, wherein at least one compartment contains the formulation of claim 1 and wherein the kit comprises instructions for administrating the formulation to a subject in need thereof.

### Claim 46

(canceled)

### Claim 47 (depends on 1)

A transdermal drug release device comprising a support layer and a layer comprising the formulation of claim 1.
